Key facts
- Iovance Biotherapeutics' stock rose on Thursday.
- Australia approved Amtagvi for melanoma patients.
- The approval is for unresectable or metastatic melanoma.
- The Australian Therapeutic Goods Administration granted the approval.
Iovance Biotherapeutics, Inc. (IOVA) experienced a stock price increase on Thursday following the approval of its melanoma therapy, Amtagvi, by the Australian Therapeutic Goods Administration. The therapy has been approved for individuals suffering from unresectable or metastatic melanoma. This regulatory green light represents a significant achievement for Iovance and offers a new treatment option for Australian patients diagnosed with advanced melanoma.
